Platelet-oriented inhibition in new TIA and minor ischemic stroke (POINT) trial: rationale and design.

ABSTRACT:

Background

Ischemic stroke and other vascular outcomes occur in 10-20% of patients in the three-months following a transient ischemic attack or minor ischemic stroke, and many are disabling. The highest risk period for these outcomes is the early hours and days immediately following the ischemic event. Aspirin is the most common antithrombotic treatment used for these patients.

Aim

The aim of POINT is to determine whether clopidogrel plus aspirin taken <12 h after transient ischemic attack or minor ischemic stroke symptom onset is more effective in preventing major ischemic vascular events at 90 days in the high-risk, and acceptably safe, compared with aspirin alone.

Design

POINT is a prospective, randomized, double-blind, multicenter trial in patients with transient

SUBMITTER: Johnston SC 

PROVIDER: S-EPMC4412261 | biostudies-literature | 2013 Aug

REPOSITORIES: biostudies-literature